Prof. Dr. Murat Binbay'ın akademik çalışmaları — tam metinleri PDF olarak indirebilirsiniz.
The FDA has approved capivasertib plus abiraterone and prednisone for PTEN-deficient mHSPC. CAPItello-281: median rPFS 33.2 months versus 25.7 months (HR 0.81).
The FDA has approved capivasertib plus abiraterone and prednisone for PTEN-deficient mHSPC. CAPItello-281: median rPFS 33.2 months versus 25.7 months (HR 0.81).
In the world's first vascularized bladder transplant, the patient voids spontaneously with a 600 mL capacity at six months and is fully continent, with no findings suggestive of rejection.
POTOMAC phase 3 trial: durvalumab plus BCG reduced the risk of recurrence or death by 32% (HR 0.68) in BCG-naive high-risk NMIBC. FDA approval on 28 May 2026.
ENLIGHTED phase 3: padeliporfin VTP produced a 70% complete response, an 88% overall response and a 23.9-month median duration of response in low-grade upper tract urothelial cancer.
BOND-003 phase 3 trial: intravesical cretostimogene produced a 75.5% complete response, a 27.9-month median duration of response and 81% bladder preservation at month 24 in BCG-unresponsive NMIBC.
New analysis of the ARCHES and PROSPER phase III trials: nearly one in four patients on enzalutamide developed radiographic progression without any PSA rise.
Results of the phase 3 trial presented at ASCO GU 2026 and published simultaneously in the New England Journal of Medicine show that a PARP inhibitor plus an androgen receptor pathway inhibitor is also effective at an earlier stage of the disease.
Pivotal data published in the Journal of Urology show that transurethral water vapour ablation may be an effective and safe focal therapy option in GG2 prostate cancer.
Answer a few questions and let Prof. Dr. Murat Binbay's team call you within 24 hours. No need to work out what to write.
Which one fits you?
Completely free · Your data stays confidential